CClinicalTrials.gg
TerminatedNCT04386668LIO-CUpdated Oct 8, 2020

Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic

An interventional study of Let It Out (LIO)-C and Neutral writing control in COVID19, sponsored by University College, London. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-08.

Sponsored by University College, London · Not applicable, Interventional, and Other

Why this study was terminated
Interim analysis indicated adaptations to intervention may be required.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A randomised controlled trial designed to test whether an online expressive writing intervention (LIO-C) can reduce distress for English-speaking adults during the global COVID19 pandemic.

Hypothesis: LIO-C will improve distress (as measured by K10) in adults at 1 week post-intervention compared to a neutral writing control during the COVID19 pandemic.

Read the detailed description

The world is currently experiencing unprecedented challenges caused by the global coronavirus (COVID19) pandemic. Many countries are enforcing measures to restrict movement of people to reduce the spread of the outbreak, including lock-downs, social distancing and self-isolation. These methods, although necessary to slow the spread of disease, will have negative effects on psychological well-being of large populations. Shortage of health care professionals and measures to restrict interpersonal contact means facilitated psychological interventions will not be feasible for many, at least during the height of the pandemic. There is therefore a need for self-directed psychological interventions that can be practically and quickly implemented online.

Emotional disclosure-based therapies, such as expressive writing (EW), hold potential as low-cost, easy to implement means of support, with minimal requirement for facilitation. In its original format, EW involved writing daily for 15-20 minutes for 3-4 days about a traumatic event. Since its development, it has been adapted in many ways, including writing about positive events and writing about stress from a compassionate stance. There is evidence that such interventions can provide significant psychological and physical benefits in healthy populations and reduce the effects of natural disasters on health and well-being. However, to our knowledge this form of psychological intervention has not been tested during a rapidly evolving crisis or pandemic.

The aim of this study is to test whether an online self-compassion and EW based intervention (LIO-C) can reduce the negative effects of the COVID19 pandemic on health and well-being. The intervention is based on an existing intervention, LIO, that we previously developed for use in advanced disease populations, in collaboration with clinical and health psychologists, and patient and public representatives. For this study, we have adapted the intervention for people living through the current COVID19 pandemic by altering the writing prompts, and translating the intervention to an online hub. As this is an unfacilitated intervention, the instructions involve writing from a compassionate stance to minimise any potential short term negative effects associated with writing about difficult experiences.

02

Conditions studied

  • COVID19

Browse trials for

Keywords

  • COVID19
  • Coronavirus
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 80 is below the median of 100 across 4,099 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

University College, London is the lead sponsor of 632 studies on the registry; 145 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • English speaking adults over the age of 18
  • Able to read and write clearly in English

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    LIO-C

    Participants receive LIO-C writing intervention

    Other: Let It Out (LIO)-C

  • Placebo comparator
    Neutral writing control

    Participants receive neutral writing control intervention

    Other: Neutral writing control

Interventions

  • OtherLet It Out (LIO)-C

    Participants complete three online 20-minute writing sessions in response to prompts asking them to write about their experiences during the COVID19 pandemic from a self-compassionate perspective

    Also known as: expressive writing, emotional disclosure, expressive disclosure, therapeutic writing

  • OtherNeutral writing control

    Participants complete three online 20-minute writing sessions in response to neutral writing prompts

06

What researchers measure

Primary outcomes

  1. Kessler Psychological Distress Scale (K10)

    10-item self-report distress scale

    Time frame: 1 week post-intervention

Secondary outcomes

  1. Kessler Psychological Distress Scale (K10)

    10-item self-report distress scale

    Time frame: Immediately and 8 weeks post-intervention

  2. Perceived Stress Scale (PSS-10)

    Self-report stress scale

    Time frame: Immediately, 1 week and 8 weeks post-intervention

  3. Pittsburgh Sleep Quality Index (PSQI)

    Self-report sleep scale

    Time frame: Immediately, 1 week and 8 weeks post-intervention

  4. Self-compassion scale (SCS)

    Self-report self-compassion scale

    Time frame: Immediately, 1 week and 8 weeks post-intervention

  5. UCLA Loneliness Scale (UCLA LS)

    Self-report loneliness scale

    Time frame: Immediately, 1 week and 8 weeks post-intervention

  6. Uptake of existing mental health services (MHS)

    Self-report measure of MHS usage

    Time frame: Immediately, 1 week and 8 weeks post-intervention

  7. Mood and meaning

    3-item, 7-point, Likert scale measuring how personal and meaningful participants' felt their writing was and their mood

    Time frame: Immediately after each writing session

  8. Acceptability

    Via an online feedback form

    Time frame: Immediately post-intervention

07

Study locations

1 site
  • University College London
    London, Kent TN14 6DW, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Fully anonymised participant data will be made available open access via ESRC data repository ReShare

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04386668
Lead sponsor
University College, London
Responsible party
Sponsor
First posted
May 13, 2020
Start date
May 26, 2020
Primary completion
Jul 12, 2020
Completion
Aug 31, 2020
Last update
Oct 8, 2020

Study contacts

Nuriye Kupeli
principal investigator · Marie Curie Palliative Care Research Department, UCL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion